References
- BangYJVan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
- LeeJLimDHKimSPhase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trialJ Clin Oncol201230326827322184384
- WadhwaRSongSLeeJSYaoYWeiQAjaniJAGastric cancer-molecular and clinical dimensionsNat Rev Clin Oncol2013101164365524061039
- CunninghamDStarlingNRaoSCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med20083581364618172173
- CervantesARodaDTarazonaNRoselloSPerez-FidalgoJACurrent questions for the treatment of advanced gastric cancerCancer Treat Rev2013391606723102520
- DallasPBPacchioneSWilskerDBowrinVKobayashiRMoranEThe human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activityMol Cell Biol20002093137314610757798
- ReismanDGlarosSThompsonEAThe SWI/SNF complex and cancerOncogene200928141653166819234488
- Cancer Genome Atlas Research, NetworkKandothCSchultzNIntegrated genomic characterization of endometrial carcinomaNature20134977447677323636398
- WiegandKCShahSPAl-AghaOMARID1A mutations in endometriosis-associated ovarian carcinomasN Engl J Med2010363161532154320942669
- WangKKanJYuenSTExome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancerNat Genet201143121219122322037554
- WangKYuenSTXuJWhole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancerNat Genet201446657358224816253
- ZangZJCutcutacheIPoonSLExome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genesNat Genet201244557057422484628
- YangLWeiSZhaoRWuYQiuHXiongHLoss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studiesSci Rep201662891927354232
- LiangHCheungLWLiJWhole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancerGenome Res201222112120212923028188
- BosseTter HaarNTSeeberLMLoss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancerMod Pathol201326111525153523702729
- WiegandKCHennessyBTLeungSA functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylationBMC Cancer20141412024559118
- KimYBHamIHHurHLeeDVarious ARID1A expression patterns and their clinical significance in gastric cancersHum Pathol201649617026826411
- SamartzisEPNoskeADedesKJFinkDImeschPARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomasInt J Mol Sci2013149188241884924036443
- SamartzisEPGutscheKDedesKJFinkDStuckiMImeschPLoss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibitionOncotarget20145145295530324979463
- ZhangQYanHBWangJChromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1Oncotarget2016729461274614127323812
- DienstmannRRodonJSerraVTaberneroJPicking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitorsMol Cancer Ther20141351021103124748656
- CourtneyKDCorcoranRBEngelmanJAThe PI3K pathway as drug target in human cancerJ Clin Oncol20102861075108320085938
- TranPNguyenCKlempnerSJTargeting the phosphatidylinositol-3-kinase pathway in gastric cancer: can omics improve outcomes?Int Neurourol J201620Suppl 2S131S14027915478
- RamanathanRKMcDonoughSLKenneckeHFPhase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)Cancer2015121132193219725827820
- GajriaDChandarlapatySHER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Rev Anticancer Ther201111226327521342044
- KatagiriANakayamaKRahmanMTLoss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinomaMod Pathol201225228228822101352
- LyuCZhangYZhouXLangJARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatinExp Ther Med20161264067407128105136